Breaking News, Trials & Filings

Mannkind’s Inhaled Insulin NDA Delayed

FDA needs more time to review

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has informed MannKind Corporation that the agency will not be able to complete the review of the NDA for Afrezza (insulin human [rDNA origin]) Inhalation Powder by the action date of December 29, 2010. The FDA stated that it will require approximately four additional weeks to complete its review of the NDA.Afrezza is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyper...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters